NAION and Wegovy: Understanding the Eye Safety Signal

What the 2024 study found, and what it did not

The research that brought NAION into the conversation came from a retrospective study conducted at Massachusetts Eye and Ear and published in JAMA Ophthalmology in July 2024. Investigators looked at medical records over several years, comparing rates of NAION in patients who had been prescribed semaglutide against those prescribed other diabetes or weight-loss medicines. In the obesity cohort, semaglutide users were roughly four times more likely to have a recorded NAION diagnosis than those taking non-GLP-1 weight-loss treatments. The numbers behind that ratio were small (20 cases against 3) but the difference held up statistically.

Two important limits apply. First, this was an observational study at a single specialist eye hospital, which almost certainly over-represents patients with pre-existing visual problems. People already attending an eye hospital are not a random sample of the population. Second, observational data can identify an association without proving causation. There are plausible biological mechanisms being investigated (including changes in cerebrospinal fluid pressure and reduced vascular supply linked to rapid fat loss) but none has been confirmed. The study's authors called for prospective research, and that work is ongoing. The MHRA's Drug Safety Update index is the right place to track how UK regulators respond as evidence accumulates.

What the study did not find is equally worth noting. There was no dose-response relationship identified, and many large semaglutide trials (including STEP 1, which ran for 68 weeks across thousands of participants) did not flag NAION as a notable adverse event. That absence of signal in prospective trials is not conclusive either way, because NAION is rare enough to be missed unless a study is specifically designed to detect it.

Who already carries a higher baseline risk of NAION

NAION has well-established risk factors that exist entirely independently of any medicine. A small, structurally crowded optic disc (sometimes called a "disc at risk") is the single strongest anatomical predictor. Beyond that, the same conditions that are common reasons to consider Wegovy for weight management are also independent NAION risk factors: type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, and cardiovascular disease.

This creates a genuine interpretive challenge. The population most likely to be prescribed semaglutide overlaps substantially with the population at elevated background risk of NAION. Disentangling the medicine's contribution from the underlying disease burden is precisely what the 2024 study could not fully do, and why regulators are cautious about strong conclusions in either direction. If you have already had NAION in one eye, the risk of a second episode in the fellow eye is meaningful regardless of treatment — your ophthalmologist's view matters most here. People with a crowded disc who have not had an episode are in a different position, and a frank conversation with a prescriber about individual risk is the right starting point rather than a blanket answer.

It is also worth keeping scale in mind. NAION affects roughly 2–10 people per 100,000 per year in the general population. Even if semaglutide carries some additional risk, the absolute numbers are low, and the benefits of sustained weight loss for cardiovascular health, blood pressure, and metabolic function are supported by robust evidence from large trials.

How this sits alongside the wider Wegovy safety picture

Every medicine involves a benefit-risk assessment, and this is no different. The MHRA reviews signals as post-market data grows; semaglutide's UK authorisation for weight management remains in place. Regulators in the US and Europe are also monitoring the NAION question, and none has moved to a contraindication or a black-box warning as of mid-2026. The NHS notes that common side effects of semaglutide are gastrointestinal (nausea, changes in bowel habit, occasional reflux) and you can read a full safety overview on the NHS semaglutide medicines page. Eye-related events are not listed as common or likely; they sit in the category of signals under active scrutiny.

If you are already on treatment and notice any sudden change in your vision (blurring, loss of part of your visual field, or anything that appears in one eye without pain) seek urgent medical assessment the same day. NAION can progress quickly and early ophthalmological review improves outcomes. This applies to anyone of any background and is not a reason to stop semaglutide abruptly without clinical advice; stopping suddenly carries its own considerations.

For some people the NAION question will be one of several things to think through alongside treatment. Questions about how semaglutide interacts with other aspects of health, from hormone replacement therapy to conditions like multiple sclerosis, come up regularly in consultations, and people sometimes also ask whether Wegovy counts as a specialty drug and what that means for how it is prescribed and accessed. The goal is always a clear-eyed assessment of individual circumstances, not a generic answer.

Making a decision with the right support

If you are considering Wegovy and the NAION signal has given you pause, that is a reasonable response to incomplete evidence, not a reason to dismiss either the treatment or the concern. The practical question is whether your individual risk profile, your weight-related health needs, and the current state of the evidence add up to a reasonable benefit-risk balance for you specifically. That is a clinical decision, not one a webpage can make.

Cost context sometimes shapes where people access treatment. Wegovy pricing in the UK varies between providers; what matters equally is whether the service behind the prescription can support you with questions like this one throughout your treatment, not just at the point of ordering. A prescriber who knows your history is better placed to flag relevant risk factors than one who has seen only a short questionnaire.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers the same day, not automated software. If you have a history of eye disease, a known disc-at-risk, or a condition that elevates your NAION background risk, that is exactly the kind of detail that shapes a prescribing decision. People also sometimes raise broader physical questions during consultations, including how Wegovy may affect the skin over the course of treatment. Our clinical team reviews each case individually, and 7-day aftercare means questions that arise after your first pen arrives (in its plain, unbranded box via DPD) reach a prescriber, not a chatbot.

If you would like to discuss your personal circumstances with a prescriber, start your free consultation and the review happens the same day.